Literature DB >> 9300070

Effect of glucocorticoids on ICP in patients with a cerebral tumour.

J Skjoeth1, P K Bjerre.   

Abstract

Preoperative treatment with glucocorticoids in patients with an intracranial tumour has been neurosurgical practice for more than 30 years. Recently, however, a less beneficial effect in patients with a meningeoma is reported. This study included 4 patients with a glioma, 4 with a metastasis and 5 with a meningeoma. All patients had a substantial amount of oedema. The effect of methylprednisolone was monitored during 5 days by clinical examination and epidural pressure measurement. ICP reduction was found in 4 of 13 patients. All observations of decreasing pressure were in patients with a malignant tumour and an initial ICP > 15 mmHg. All 4 patients improved clinically. Another 4 patients with a benign meningioma had a significant increase of ICP and none of them experienced clinical improvement. Clinical deterioration was not observed in any patient despite increasing ICP in some cases. In summary, a beneficial effect of GC was demonstrated only in patients with a malignant tumour and augmented pre-treatment ICP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300070     DOI: 10.1111/j.1600-0404.1997.tb00261.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  Compression stiffening of brain and its effect on mechanosensing by glioma cells.

Authors:  Katarzyna Pogoda; LiKang Chin; Penelope C Georges; FitzRoy J Byfield; Robert Bucki; Richard Kim; Michael Weaver; Rebecca G Wells; Cezary Marcinkiewicz; Paul A Janmey
Journal:  New J Phys       Date:  2014-07       Impact factor: 3.729

2.  Intrathecal corticoids in permanent focal cerebral ischemia in rats. Part I: a new therapeutic approach in the acute phase.

Authors:  Sophia L Goericke; Tobias Engelhorn; Michael Forsting; Ulrich Speck; Stefan Maderwald; Mark E Ladd; Arnd Doerfler
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.